Mizuho Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $20

Benzinga · 01/07 16:09
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and raises the price target from $19 to $20.